{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:29:07Z","timestamp":1791523747087,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2020GXNSFAA159019"],"award-info":[{"award-number":["2020GXNSFAA159019"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejpb.2026.115075","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:02:47Z","timestamp":1776142967000},"page":"115075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Improving oral bioavailability and tabletability of celecoxib by preparing its three cocrystals"],"prefix":"10.1016","volume":"223","author":[{"given":"Jingjing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghua","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.ejpb.2026.115075_b0005","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"8982","key":"10.1016\/j.ejpb.2026.115075_b0010","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(95)91782-9","article-title":"NSAIDs, Cox-2 inhibitors, and the gut","volume":"346","author":"Bennett","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115075_b0015","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jps.20522","article-title":"Characterization of a novel polymorphic form of celecoxib","volume":"95","author":"Lu","year":"2006","journal-title":"J. Pharm. Sci."},{"issue":"14","key":"10.1016\/j.ejpb.2026.115075_b0020","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1080\/14656566.2019.1645123","article-title":"Celecoxib for the treatment of musculoskeletal arthritis","volume":"20","author":"Krasselt","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejpb.2026.115075_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173325","article-title":"MicroRNAs in the anticancer effects of celecoxib: a systematic review","volume":"882","author":"Mishan","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejpb.2026.115075_b0030","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200326","article-title":"Recent advances in the development of celecoxib analogs as anticancer agents: a review","volume":"355","author":"Abdelhaleem","year":"2022","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejpb.2026.115075_b0035","series-title":"Polymorphic crystalline forms of celecoxib","author":"Leonard","year":"2000"},{"key":"10.1016\/j.ejpb.2026.115075_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120239","article-title":"Direct compression tablet formulation of celecoxib enabled with a pharmaceutical solvate","volume":"596","author":"Wang","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.ejpb.2026.115075_b0045","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1248\/cpb.c16-00233","article-title":"Characterization and Quality Control of Pharmaceutical Cocrystals","volume":"64","author":"Izutsu","year":"2016","journal-title":"Chem. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115075_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10030098","article-title":"Co-Amorphous Solid Dispersions for Solubility and Absorption Improvement of drugs: Composition, Preparation, Characterization and Formulations for Oral delivery","volume":"10","author":"Karagianni","year":"2018","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115075_b0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/17425247.2013.747508","article-title":"Cocrystallization for successful drug delivery","volume":"10","author":"Sun","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115075_b0060","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1021\/acs.cgd.6b00266","article-title":"Improving the Solubility and Bioavailability of Apixaban via Apixaban\u2013Oxalic Acid Cocrystal","volume":"16","author":"Yong","year":"2016","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2026.115075_b0065","doi-asserted-by":"crossref","unstructured":"Bing X, Yaping L, Xiaotong L, Pei Y, Wei H. Solubilization techniques used for poorly water-soluble drugs. Acta Pharmaceutica Sinica B. 202;14(11):4683-4716. Doi: 10.1016\/j.apsb.2024.08.027.","DOI":"10.1016\/j.apsb.2024.08.027"},{"key":"10.1016\/j.ejpb.2026.115075_b0070","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.addr.2007.05.010","article-title":"Salt Formation to Improve Drug Solubility","volume":"59","author":"Serajuddin","year":"2007","journal-title":"Adv. Drug Delivery Rev."},{"issue":"11","key":"10.1016\/j.ejpb.2026.115075_b0075","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1021\/acs.molpharmaceut.3c00727","article-title":"Comparative Evaluation of Particle size Reduction, Salt Formation, and Amorphous Formulation on the Biopharmaceutical Performance of a Weak Base Drug Candidate","volume":"20","author":"Wei","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115075_b0080","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11814-010-0520-0","article-title":"Solid forms of pharmaceuticals: Polymorphs, salts and cocrystals","volume":"28","author":"Bipul","year":"2011","journal-title":"Korean J. Chem. Eng."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115075_b0085","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jps.20302","article-title":"Trends in solubility of polymorphs","volume":"94","author":"Pudipeddi","year":"2005","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115075_b0090","first-page":"713","article-title":"Polymorphism in solid dispersions","volume":"20","author":"Karina","year":"2019","journal-title":"Cryst. Growth Des."},{"issue":"10","key":"10.1016\/j.ejpb.2026.115075_b0095","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1021\/cg500509c","article-title":"Polymorphism of anti-HIV drug efavirenz: investigations on thermodynamic and dissolution properties","volume":"14","author":"Cinira","year":"2014","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2026.115075_b0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2017.03.002","article-title":"Pharmaceutical solvates, hydrates and amorphous forms: a special emphasis on cocrystals","volume":"117","author":"Anne","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2026.115075_b0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijpharm.2018.10.044","article-title":"Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid\/saccharin for improvement of wettability and dissolution rate","volume":"554","author":"Sang-Min","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115075_b0110","first-page":"95","article-title":"Co-amorphous solid dispersion systems of lacidipine-spironolactone with improved dissolution rate and enhanced physical stability","volume":"14","author":"Zhaomeng","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115075_b0115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/molecules28020613","article-title":"Recent advances in pharmaceutical cocrystals: a focused review of flavonoid cocrystals","volume":"28","author":"Jia","year":"2023","journal-title":"Molecules"},{"issue":"117","key":"10.1016\/j.ejpb.2026.115075_b0120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.addr.2017.07.008","article-title":"Advanced methodologies for cocrystal synthesis","volume":"1","author":"Douroumis","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.ejpb.2026.115075_b0125","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.apsb.2021.03.030","article-title":"Pharmaceutical cocrystals: a review of preparations, physicochemical properties and applications","volume":"11","author":"Minshan","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115075_b0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1389450124666221114095400","article-title":"A comprehensive insight on pharmaceutical co-crystals for improvement of aqueous solubility","volume":"24","author":"Malik","year":"2023","journal-title":"Curr. Drug Targets"},{"issue":"11","key":"10.1016\/j.ejpb.2026.115075_b0135","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1021\/acs.cgd.2c01553","article-title":"Pharmaceutical Cocrystals: a Perspective on Development and Scale-up of solution Cocrystallization","volume":"23","author":"Anindita","year":"2023","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2026.115075_b0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejpb.2020.05.031","article-title":"Structure-mechanics and improved tableting performance of the drug-drug cocrystal metformin: salicylic acid","volume":"153","author":"Jayshil","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115075_b0145","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1021\/cg3002948","article-title":"Polymorphs, salts, and cocrystals: what\u2019s in a name?","volume":"12","author":"Srinivasulu","year":"2012","journal-title":"Cryst. Growth Des."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115075_b0150","first-page":"307","article-title":"Drug-drug cocrystals: Opportunities and challenges","volume":"16","author":"Xiaojuan","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"issue":"S1","key":"10.1016\/j.ejpb.2026.115075_b0155","doi-asserted-by":"crossref","first-page":"17S","DOI":"10.1111\/j.2042-7158.1970.tb08574.x","article-title":"Some observations on the ageing of sodium chloride compacts","volume":"22","author":"Rees","year":"1970","journal-title":"J. Pharm. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115075_b0160","first-page":"52","article-title":"Evolutions in direct compression","volume":"29","author":"Mccormick","year":"2005","journal-title":"Pharm. Technol."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115075_b0165","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/cryst13040640","article-title":"Structural Characterization of Pharmaceutical Cocrystals with the use of Laboratory X-ray Powder Diffraction patterns","volume":"13","author":"Chernyshev","year":"2023","journal-title":"Crystals"},{"issue":"5","key":"10.1016\/j.ejpb.2026.115075_b0170","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11095-022-03243-9","article-title":"Combination of co-crystal and nanocrystal techniques to improve the solubility and dissolution rate of poorly soluble drugs","volume":"39","author":"Huang","year":"2022","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.ejpb.2026.115075_b0175","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1002\/jps.24048","article-title":"Baicalein\u2013Nicotinamide Cocrystal with Enhanced Solubility, Dissolution, and Oral Bioavailability","volume":"103","author":"Yanting","year":"2014","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.ejpb.2026.115075_b0180","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3390\/molecules23092136","article-title":"DSC, FTIR and Raman spectroscopy coupled with multivariate analysis in a study of co-crystals of pharmaceutical interest","volume":"23","author":"Garbacz","year":"2018","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.ejpb.2026.115075_b0185","first-page":"1773","article-title":"Nanoscale celecoxib prodrugs: As efficient anti-inflammatory principles","volume":"90","author":"Rudaba","year":"2023","journal-title":"J DRUG DELIV SCI TEC."},{"key":"10.1016\/j.ejpb.2026.115075_b0190","article-title":"Volumetric studies for glycine in aqueous L-tartaric acid to find intermolecular interactions at different temperatures along with FTIR and thermal stability","author":"Tarnveer","year":"2025","journal-title":"J Mol Liq. 418"},{"issue":"10","key":"10.1016\/j.ejpb.2026.115075_b0200","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3390\/plants10102158","article-title":"Encapsulation of Cinnamic Acid on Plant-based Proteins: Evaluation by HPLC, DSC and FTIR-ATR","volume":"10","author":"Mirela","year":"2021","journal-title":"Plants"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115075_b0205","first-page":"78","article-title":"Solubility of drugs, their Enhancement, Factors Affecting and their Limitations: a Review","volume":"79","author":"Asim","year":"2023","journal-title":"Int J Pharm Sci Rev Res."},{"issue":"11","key":"10.1016\/j.ejpb.2026.115075_b0210","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/cryst10110996","article-title":"Discovery, Characterization, and Pharmaceutical applications of two Loratadine\u2013Oxalic Acid Cocrystals","volume":"10","author":"Zhengxuan","year":"2020","journal-title":"Crystals"},{"issue":"3","key":"10.1016\/j.ejpb.2026.115075_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pcrysgrow.2016.07.001","article-title":"Spring and parachute: how cocrystals enhance solubility","volume":"62","author":"Bavishi","year":"2016","journal-title":"Prog. Cryst. Growth Charact. Mater."},{"issue":"33","key":"10.1016\/j.ejpb.2026.115075_b0220","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.2174\/0929867325666180322145335","article-title":"In-Vitro Drug Dissolution Studies in Medicinal Compounds","volume":"25","author":"Burcin","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115075_b0225","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1021\/acs.cgd.6b01848","article-title":"Co-Crystal of Tramadol hydrochloride\u2013Celecoxib (CTC): a novel API\u2013API co-crystal for the treatment of pain","volume":"17","author":"Carmen","year":"2017","journal-title":"Cryst. Growth Des."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115075_b0230","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijpharm.2013.05.038","article-title":"FEM simulation of the die compaction of pharmaceutical products: influence of visco-elastic phenomena and comparison with experiments","volume":"453","author":"Harona","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115075_b0235","article-title":"The role of cocrystallization-mediated altered crystallographic properties on the tabletability of rivaroxaban and malonic acid","volume":"12(6):546","author":"Dnyaneshwar","year":"2020","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.ejpb.2026.115075_b0240","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1039\/C9CE01874C","article-title":"The landscape of mechanical properties of molecular crystals","volume":"22","author":"Chenguang","year":"2020","journal-title":"CrstEngComm"},{"issue":"9","key":"10.1016\/j.ejpb.2026.115075_b0245","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1517\/17425255.2014.942281","article-title":"Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics","volume":"10","author":"Ning","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115075_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/js9601896","article-title":"Characteristics and significance of the Amorphous State in Pharmaceutical Systems","volume":"86","author":"Hancock","year":"1997","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:18:26Z","timestamp":1782821906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":49,"alternative-id":["S0939641126000962"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115075","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving oral bioavailability and tabletability of celecoxib by preparing its three cocrystals","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115075"}}